ABOUT PANGEA LABORATORY

Advancing Clinical Outcomes with Breakthrough Diagnostic Insights

Who We Are

Pangea Laboratory is a California-based CLIA-certified, CAP-accredited laboratory, specializing in next-generation sequencing (NGS) and molecular diagnostics. Our scientific expertise, focus on quality, and strong regulatory foundation ensure clinicians and researchers can move medicine forward.

Proof Points

Explore our laboratory developed tests: from concept to test development and regulatory approval. An outstanding example is our noninvasive Bladder CARE™ Test, which has been granted with the FDA Breakthrough Designation Device.

Our Services

Comprehensive services designed to enable progress from research concept to clinical application and commercialization.

Client Testimonials

Pangea Laboratory’s accredited facilities, proprietary workflows, and scientific rigor ensure reliable data and reproducible outcomes for clients globally, across clinical, academic, and industrial sectors.

CLIA Certified and CAP Accredited

Pangea Laboratory operates under CLIA certification and CAP accreditation, representing the highest standards in laboratory quality and compliance. Our laboratory consistently meets and exceeds federal and professional benchmarks for precision, validity, and excellence in diagnostic testing.

"At Pangea Laboratory, we believe patients and healthcare providers need answers—and they need them sooner. Whether partnering with organizations to bring impactful new tests to market or developing our own diagnostic solutions, our mission is to deliver accurate, actionable results that empower discovery, accelerate innovation, and bring reliable diagnostics to everyone."

– John Moore, Pangea Laboratory CEO

Meet Our Leadership Team

Mr. Moore joined Pangea Laboratory as CEO in early 2025, bringing 25 years of commercial and operational leadership in the pharmaceutical and diagnostic laboratory sectors. A hands-on leader, he has guided organizations large and small to success. At Pangea, he’s focused on building a strong and scalable foundation for long-term expansion.

John Moore

Chief Executive Officer

Dr. Jia founded Pangea Laboratory in 2014. He is also the founder and President of Zymo Research Corp, a leader in epigenetics and microbiomics. A virologist by training, he discovered the West Nile virus in North America in 1999 and was previously faculty at the University of California, Irvine.

Dr. Larry Jia

Founder / Chairman

Dr. Booher has over 15 years’ experience in biotech and utilizes Next Generation Sequencing technology to address the most challenging problems in molecular biology. The Principal Investigator on over $12 million in research grants and contracts from federal and local entities, he couples advanced multi-omics workflows with AI and ML analytical tools to drive innovation in the MedTech sector.

Dr. Keith Booher

VP of NGS Solutions

Dr. Yap Ching Chew leads clinical diagnostics and in vitro diagnostics (IVD) strategy across oncology and broader diagnostic applications. She has guided the laboratory to CLIA certification and CAP accreditation and oversees the translation of epigenetic and molecular technologies into clinically validated, regulatory-aligned diagnostic solutions.

Dr. Yap Ching Chew

Chief Operating Officer / Director of Clinical Development

Dr. Piatti is the Chief Scientific Officer at Pangea Laboratory, where he leads the research and development of innovative non-invasive diagnostic tests, with a particular focus on oncology. He joined the company as a Project Manager in 2017 and has over 20 years of experience in assay development, epigenetics, and molecular biology.

Dr. Paolo Piatti

Chief Scientific Officer

Mr. Pratt joined Pangea in 2023 with 25+ years in clinical diagnostics and commercial leadership across Europe, Asia, and the Americas. As Senior Director of Commercialization, he drives product launches and partnerships. He previously held roles at bioMérieux and Bio-Rad.

Simon Pratt

Sr. Director Business Development

Dr. Putcha is a molecular pathologist with broad experience across academia, industry, venture/private equity, regulatory and payer coverage for molecular diagnostic tests. He previously served as Director of Laboratory Science at MolDX and as a member of the Medicare Evidence Development & Coverage Advisory Committee.

Dr. Girish Putcha

Chief Medical Officer / Sr. VP Market Access

Dr. Redford is a Postdoctoral Research Scientist specializing in the PrecisionBIOME® NGS assay. She holds a Ph.D. in Biomedical Sciences from UC Irvine and a B.S. in Microbiology from the University of Minnesota. Her research spans microbial physiology, environmental microbiology, and electrophysiology.

Dr. Kaitlyn Redford

Postdoctoral Research Scientist

Dr. Savala is board-certified in Anatomic/Clinical Pathology and Hematopathology with 20+years of leadership experience. He completed his fellowship in Hematopathology at Cedars-Sinai Medical Center and has held laboratory director roles at multiple organizations, bringing expertise in molecular diagnostics, oncology testing, and regulatory compliance.

Dr. Jess Savala

Lab Director

Ms. Tran is a technical expert with over 25 years’ experience in clinical and pharmaceutical labs, and a long history of building high-performing teams in Lab Operations. Her strengths lie in regulatory (CLIA/CAP/NY) compliance, workflow optimization and molecular assay validation.

Linh Tran

Clinical Laboratory Manager

Latest News + Insights

Explore how Pangea Laboratory is shaping the future of precision diagnostics, from NGS innovations to clinical assay development.

Partners

Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA

The GA-map® MHI GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration…

Pangea in the News

Pangea Laboratory Appoints John Moore as Chief Executive Officer

Partnerships

Pangea Laboratory Partners with Unilabs to Introduce Bladder CARE™ Assay…

Research

Pangea Laboratory Receives FDA Breakthrough Device Designation for the Bladder CARE™ Assay

The Bladder CARE™ Assay measures the methylation levels of three urothelial cancer-specific DNA biomarkers in a single qPCR reaction. It markedly outperforms traditional cytology…

Find us in Tustin, California

Located in the heart of Orange County, Pangea Laboratory sits within Southern California’s “Biotech Beach’, a powerhouse region spanning San Diego to Los Angeles widely acknowledged as one of the nation’s leading life science hubs.

Scroll to Top

Custom Sequencing Solutions

Have questions? Contact us for more details.

PrecisionBIOME™

A targeted NGS platform developed for the comprehensive detection and characterization of bacterial and fungal pathogens, viral agents (HSV/HPV), and sexually transmitted infections (STIs), alongside the molecular profiling of antimicrobial resistance (AMR) markers for clinical diagnostics in vaginal and uterine specimens – Coming in Q2 2026.

Have questions? Contact us for more details.